Church & Dwight Q1
This article was originally published in The Tan Sheet
Executive SummaryConsumer products firm to reinvest "a high percentage" of benefits from Carter-Wallace acquisition in marketing, product development, CEO Robert Davies tells analysts May 6. Strategy will "moderate profit growth for the next two or three quarters," firm says. Upcoming initiatives include ad, marketing support to boost flat Arrid sales, slumping oral care business. Net sales jumped 52% to $353.3 mil. in Q1; net income rose 23% to $14.9 mil. Excluding Armkel, C&D sales increased 13.2% to $256.8 mil. Arrid addition helped push consumer revenue up 15.9% to $212.8 mil...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.